Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mark S. Rubin
Observed name:
Mark Rubin
Institutions:
Sarah Cannon Research Institute,
Sarah Cannon,
Florida Cancer Specialists & Research Institute,
Tennessee Oncology
Observed institutions:
Memorial Sloan Kettering Cancer Center,
Sarah Cannon Research Institute,
Sarah Cannon,
Florida Cancer Specialists & Research Institute,
Center for Cancers and Blood Disorders,
Tennessee Oncology
show all 6
OpenAlex ID:
A5103466743
Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute
2012
·
John D. Hainsworth
, Mark S. Rubin
, et al.
·
Journal of Clinical Oncology
·
383
Phase II Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients with Advanced Pancreatic Cancer
2009
·
Muhammad Saif
, Nikolai Podoltsev
, et al.
·
Cancer Investigation
·
96
Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: A phase 2 trial of the Sarah Cannon Oncology Research Consortium
2010
·
John D. Hainsworth
, Jeffrey R. Infante
, et al.
·
Cancer
·
87
Pazopanib as Second-Line Treatment After Sunitinib or Bevacizumab in Patients With Advanced Renal Cell Carcinoma: A Sarah Cannon Oncology Research Consortium Phase II Trial
2013
·
John D. Hainsworth
, Mark S. Rubin
, et al.
·
Clinical Genitourinary Cancer
·
52
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer
2012
·
David R. Spigel
, F. Anthony Greco
, et al.
·
Lung Cancer
·
41
Insulin‐like growth factors modulate the growth inhibitory effects of retinoic acid on MCF‐7 breast cancer cells
1995
·
Jacqueline M. Bentel
, David E. Lebwohl
, et al.
·
Journal of Cellular Physiology
·
36
Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium
2013
·
Ralph J. Hauke
, Jeffrey R. Infante
, et al.
·
Melanoma Research
·
21
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI)
2017
·
David R. Spigel
, Mark S. Rubin
, et al.
·
Lung Cancer
·
17
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).
2012
·
Victor Gian
, Mark S. Rubin
, et al.
·
Journal of Clinical Oncology
·
6
Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients (pts) with carcinoma of unknown primary site (CUP): Results of a prospective Sarah Cannon Research Institute (SCRI) trial.
2012
·
Frank A. Greco
, Mark S. Rubin
, et al.
·
Journal of Clinical Oncology
·
4
Small-Cell Lung Carcinoma: An Analysis of 194 Consecutive Patients
1998
·
Daniel E. Dosoretz
, James H. Rubenstein
, et al.
·
American Journal of Clinical Oncology
·
4
Everolimus in combination with paclitaxel and carboplatin in patients with advanced melanoma: A phase II trial of the Sarah Cannon Research Institute (SCRI).
2012
·
Ralph J. Hauke
, Jeffrey R. Infante
, et al.
·
Journal of Clinical Oncology
·
2
Reply to M.-E. Percival et al and L.B. Saltz
2013
·
John D. Hainsworth
, David R. Spigel
, et al.
·
Journal of Clinical Oncology
PDF
Gene expression profiling for prediction of tissue of origin to direct site-specific therapy in patients with CUP: Treatment outcomes by assay predictive probability.
2012
·
Mark S. Rubin
, Frank A. Greco
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
14
Citation count:
749
H-index:
8
I10-index:
8
Year
Topic
Type